Photographer: Daniel Acker/Bloomberg

Mylan Agrees to $465 Million EpiPen Settlement With U.S.

  • Shares gain late Friday after drugmaker announces agreement
  • Company also gets inquiry from SEC asking about Medicaid

Mylan NV will pay the U.S. government $465 million in a swift settlement over how the drugmaker charged Medicaid for its allergy shot EpiPen.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.